

## **NEWS RELEASE**

## **RECORDATI: PUBLIC DISCLOSURE**

Milan, 19 March 2018 – Please be informed that the 2017 Report on Remuneration approved by the Board of Directors on 15<sup>th</sup> March 2018 is available to the public, as of today, at the Company's registered office and published on the Company's website (<a href="www.recordati.it">www.recordati.it</a>; Section Corporate Governance) and on the "1info" storage mechanism (<a href="www.linfo.it">www.linfo.it</a>).

Furthermore, please be informed that the 2017 consolidated non-financial information disclosure pursuant to Legislative Decree n. 254 dated 30 December 2016, approved by the Board of Directors on 15<sup>th</sup> March 2018, is available to the public, as of today, by the means indicated above (with reference to the Company's website: Section Investors).

**Recordati**, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, other Central and Eastern European countries, Turkey, North Africa, the United States of America, Canada, Mexico and in some South American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2017 was € 1,288.1 million, operating income was € 406.5 million and net income was € 288.8 million

For further information:

Recordati website: www.recordati.com

Investor Relations
Marianne Tatschke
(39)0248787393

e-mail: investorelations@recordati.it

Media Relations
Studio Noris Morano

(39)0276004736, (39)0276004745

e-mail: norismorano@studionorismorano.com